118 related articles for article (PubMed ID: 38583810)
21. Brusatol reverses lipopolysaccharide-induced epithelial-mesenchymal transformation and induces apoptosis through PI3K/Akt/NF-кB pathway in human gastric cancer SGC-7901 cells.
Chen H; Jiang T; Chen H; Su J; Wang X; Cao Y; Li Q
Anticancer Drugs; 2021 Apr; 32(4):394-404. PubMed ID: 33229902
[TBL] [Abstract][Full Text] [Related]
22. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
23. Brusatol-Mediated Inhibition of c-Myc Increases HIF-1α Degradation and Causes Cell Death in Colorectal Cancer under Hypoxia.
Oh ET; Kim CW; Kim HG; Lee JS; Park HJ
Theranostics; 2017; 7(14):3415-3431. PubMed ID: 28912885
[TBL] [Abstract][Full Text] [Related]
24. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2.
Olayanju A; Copple IM; Bryan HK; Edge GT; Sison RL; Wong MW; Lai ZQ; Lin ZX; Dunn K; Sanderson CM; Alghanem AF; Cross MJ; Ellis EC; Ingelman-Sundberg M; Malik HZ; Kitteringham NR; Goldring CE; Park BK
Free Radic Biol Med; 2015 Jan; 78():202-12. PubMed ID: 25445704
[TBL] [Abstract][Full Text] [Related]
25. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
26. Brusatol inhibits HIF-1 signaling pathway and suppresses glucose uptake under hypoxic conditions in HCT116 cells.
Lu Y; Wang B; Shi Q; Wang X; Wang D; Zhu L
Sci Rep; 2016 Dec; 6():39123. PubMed ID: 27982118
[TBL] [Abstract][Full Text] [Related]
27. UVA Irradiation Enhances Brusatol-Mediated Inhibition of Melanoma Growth by Downregulation of the Nrf2-Mediated Antioxidant Response.
Wang M; Shi G; Bian C; Nisar MF; Guo Y; Wu Y; Li W; Huang X; Jiang X; Bartsch JW; Ji P; Zhong JL
Oxid Med Cell Longev; 2018; 2018():9742154. PubMed ID: 29670684
[TBL] [Abstract][Full Text] [Related]
28. Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc.
Mata-Greenwood E; Cuendet M; Sher D; Gustin D; Stock W; Pezzuto JM
Leukemia; 2002 Nov; 16(11):2275-84. PubMed ID: 12399973
[TBL] [Abstract][Full Text] [Related]
29. Nck2 Deficiency in Mice Results in Increased Adiposity Associated With Adipocyte Hypertrophy and Enhanced Adipogenesis.
Dusseault J; Li B; Haider N; Goyette MA; Côté JF; Larose L
Diabetes; 2016 Sep; 65(9):2652-66. PubMed ID: 27325288
[TBL] [Abstract][Full Text] [Related]
30. Redox-sensitive micelles composed of disulfide-linked Pluronic-linoleic acid for enhanced anticancer efficiency of brusatol.
Zhang J; Fang X; Li Z; Chan HF; Lin Z; Wang Y; Chen M
Int J Nanomedicine; 2018; 13():939-956. PubMed ID: 29491708
[TBL] [Abstract][Full Text] [Related]
31. Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation.
Cuendet M; Gills JJ; Pezzuto JM
Cancer Lett; 2004 Mar; 206(1):43-50. PubMed ID: 15019158
[TBL] [Abstract][Full Text] [Related]
32. MiR-497-3p induces Premature ovarian failure by targeting KLF4 to inactivate Klotho/PI3K/AKT/mTOR signaling pathway.
Zhou Y; Yuan F; Jia C; Chen F; Li F; Wang L
Cytokine; 2023 Oct; 170():156294. PubMed ID: 37549487
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic, metabolic profiling and elimination of brusatol in rats.
Guo N; Xu X; Yuan G; Chen X; Wen Q; Guo R
Biomed Chromatogr; 2018 Dec; 32(12):e4358. PubMed ID: 30089336
[TBL] [Abstract][Full Text] [Related]
34. circ_VMA21 protects WI-38 cells against LPS-induced apoptotic and inflammatory injury by acting on the miR-409-3p/KLF4 axis.
Wang Q; Zhang X; Chen D
Gen Physiol Biophys; 2021 Jul; 40(4):275-287. PubMed ID: 34350833
[TBL] [Abstract][Full Text] [Related]
35. KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
Riverso M; Montagnani V; Stecca B
Oncogene; 2017 Jun; 36(23):3322-3333. PubMed ID: 28068326
[TBL] [Abstract][Full Text] [Related]
36. Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures.
Rossow L; Eke I; Dickreuter E; Cordes N
Oncol Rep; 2015 Jul; 34(1):469-76. PubMed ID: 26004008
[TBL] [Abstract][Full Text] [Related]
37. miR-148-3p and miR-152-3p synergistically regulate prostate cancer progression via repressing KLF4.
Feng F; Liu H; Chen A; Xia Q; Zhao Y; Jin X; Huang J
J Cell Biochem; 2019 Oct; 120(10):17228-17239. PubMed ID: 31104329
[TBL] [Abstract][Full Text] [Related]
38. miR-302a-3p suppresses melanoma cell progression via targeting METTL3.
Chang X; Lin YY; Bai LN; Zhu W
J Chemother; 2022 Feb; 34(1):55-66. PubMed ID: 34286671
[TBL] [Abstract][Full Text] [Related]
39. Nck1, But Not Nck2, Mediates Disturbed Flow-Induced p21-Activated Kinase Activation and Endothelial Permeability.
Alfaidi M; Bhattarai U; Orr AW
J Am Heart Assoc; 2020 Jun; 9(11):e016099. PubMed ID: 32468886
[TBL] [Abstract][Full Text] [Related]
40. Nck2, an unexpected regulator of adipogenesis.
Haider N; Dusseault J; Rudich A; Larose L
Adipocyte; 2017 Apr; 6(2):154-160. PubMed ID: 28425845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
